# CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

> **NCT03851237** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 69 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** 64Cu-DOTA-ECLIi
- **DEVICE:** PET/CT

## Key facts

- **NCT ID:** NCT03851237
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-02
- **Primary completion:** 2025-12-19
- **Final completion:** 2025-12-19
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03851237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03851237, "CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT03851237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*